Allogeneic bone marrow vs. peripheral blood stem cell transplantation: A long-term retrospective single-center analysis in 329 patients

European Journal of Haematology

Volumn 87, Issue 6, 2011, Pages 531-538

  Auberger, Jutta ^a,b   Clausen, Johannes ^a,b   Kircher, Brigitte ^a   Kropshofer, Gabriele ^c   Lindner, Beate ^a   Nachbaur, David ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Private Medical University Hospital   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Allogeneic; Bone marrow; Graft versus host disease; Long term outcome; Peripheral blood; Retrospective; Stem cell transplantation

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 81255159083     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01692.x     Document Type: Article

References (43)

1. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Frauendorfer K, European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5years. Bone Marrow Transplant 2011;46:485-501.
2. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-8.
3. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995;85:1659-65.
4. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russell NH. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (GCSF). Blood 1995;85:1666-72.
5. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996;88:2794-800.
6. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells versus bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000;95:3702-9.
7. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematological malignancies. Bone Marrow Transplant 1998;22:1145-51.
8. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukemia: a report from the Societe′ Francaise de Greffe de Moelle. J Clin Oncol 2000;18:537-46.
9. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, Solheim BG, Evensen SA. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000;25:1129-36.
10. Powles R, Mehta R, Kulkami S, et al. Allogeneic blood and bone marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355:1231-7.
11. Bensinger W, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
12. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-9.
13. Lapierre V, Oubouzar N, Auperin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001;97:2580-6.
14. Tanimoto TE, Yamaguchi T, Tanaka Y, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004;125:480-93.
15. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;15:100.
16. Stem Cell Trialists' Cooperative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
17. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005;105:548-51.
18. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001;98:1739-45.
19. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002;100:3128-34.
20. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O, Wagner JE. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004;22:4872.
21. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone in HLA-matched sibling donor transplants for young patients with severe aquired aplastic anemia. Blood 2007;110:1397.
22. Pallua S, Giesinger J, Oberguggenberger A, Kemmler G, Nachbaur D, Clausen J, Kopp M, Sperner-Unterweger B, Holzner B. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant 2010;45:1534-9.
23. McCullough J, Kahn J, Adamson J, et al. Hematopoietic growth factors - use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008;48:2008-25.
24. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-35.
25. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic stem cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-4000.
26. Nachbaur D, Eibl B, Kropshofer G, Meister B, Mitterschiffthaler A, Schennach H, Fischer G, Kopp M, Gunsilius E, Gastl G. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002;11:731-7.
27. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human reci pients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-301.
28. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GF, Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-11.
29. Marr K, Seidel K, Slavin M, Bowden R, Schoch H, Flowers M, Corey L, Boeckh M. Prolonged fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. Blood 2002;96:2055-61.
30. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999;18:695-706.
32. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001;19:3685-91.
33. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108:4288-90.
34. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002;100:761-7.
35. Schmitz N, Beksac M, Bacigalupo A, et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005;90:643-8.
36. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Beksac M, Hasenclever D, Socié G, Schmitz N. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010;11:331-8.
37. Ringdén OT, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol 2005;33:505-12.
38. Bensinger W, on behalf of the Stem Cell Trialists' Cooperative Group. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplantat vs. bone marrow transplant in the management of haematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006;38:539-46.
39. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999;94:1465-70.
40. Gallardo D, de la Cámara R, Nieto JB, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009;94:1282-8.
41. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100:1525-31.
42. Cornelissen JJ, van der Holt B, Petersen EJ, et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003;31:855-64.
43. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;15:102.